INDVMEDIUM SIGNALFINANCIAL10-K

INDV substantially reduced share buyback activity while improving its balance sheet position through meaningful debt reduction and equity improvement.

The dramatic pullback in share buybacks from $173M to $11M suggests management is prioritizing balance sheet preservation over shareholder returns, which could indicate either capital constraints or strategic repositioning. The simultaneous $400M reduction in total liabilities and significant improvement in stockholders' equity from negative $348M to negative $98M demonstrates meaningful progress in deleveraging efforts.

Comparing 2026-02-26 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

INDV's financial position shows a mixed but improving picture, with total liabilities declining notably from $1.7B to $1.3B while stockholders' equity improved substantially though remaining in negative territory. Cash reserves declined moderately to $195M alongside reduced current assets and inventory levels, suggesting either strategic asset optimization or constrained liquidity management. The company appears to be prioritizing debt reduction and balance sheet repair over aggressive capital deployment, as evidenced by the sharp reduction in share repurchase activity.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-93.6%
$173.0M$11.0M

Buyback activity reduced 93.6% — capital being redeployed elsewhere or cash conservation underway.

Stockholders Equity
Balance Sheet
+71.8%
-$348.0M-$98.0M

Equity base grew 71.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
-38.9%
$319.0M$195.0M

Cash declined 38.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-22.3%
$839.0M$652.0M

Current assets declined 22.3% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-22.1%
$1.7B$1.3B

Liabilities reduced 22.1% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
-14%
$178.0M$153.0M

Inventory reduced 14% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-03
ADDED
(Exact name of registrant as specified in its charter) Delaware 41-2520873 State or other jurisdiction of incorporation or organization (I.R.S.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
147 SIGNATURES 148 i GLOSSARY ANDA means an abbreviated new drug application filed with the FDA.
Aquestive means Aquestive Therapeutics, a third-party CMO that manufactures and supplies SUBOXONE Film exclusively for us.
BMAT means buprenorphine-medically assisted treatment, the process to treat OUD patients treated with Buprenorphine (as opposed to methadone or other medicines).
or its affiliate Curia New Mexico, LLC, as the context requires, a third-party CMO who manufactures SUBLOCADE exclusively for us.
HMRC means His Majesty's Revenue and Customs, the taxing authority in the U.K.
IND means an investigational new drug application filed with the FDA.
In particular, our actual results, performance or achievements or industry results could be affected by, among other things: We are subject to risks related to the manufacture and distribution of our products and must adhere to stringent manufacturing processes.
5 ABOUT THIS ANNUAL REPORT As used herein, references to we, us, the Company, Indivior, Indivior Pharmaceuticals, Indivior Group or the Group, or similar terms in this Form 10-K mean Indivior Pharmaceuticals, Inc.
REMOVED
As of March 1, 2025, the number of outstanding ordinary shares was 124,655,858 .
8 Overview 8 Industry Overview 12 Indivior Products 16 Competition 19 Research and Development 19 Pipeline 21 Manufacturing and Supply 21 Sales, Marketing and Distribution 23 Intellectual Property 28 Regulatory Overview 29 Environmental 42 Human Capital 43 Other Information and Corporate Governance 44 Item 1A.
162 Election of Directors 164 Family Relationships 168 Agreement with Significant Shareholder 168 Code of Ethics 168 Shareholder Nominations for Directors 168 Audit Risk Committee 169 Audit Committee Financial Expert 169 i Insider 170 Policies 170 Item 11.
171 Total Compensation for the Chair and Non-Executive Directors 171 Compensation of Executive Directors and Senior Managers 172 Annual Incentive Plan ( AIP ) 172 Indivior PLC Long-Term Incentive Plan ( LTIP ) 174 Indivior Share Plans 174 The Indivior 2024 Long-Term Incentive Plan (the LTIP ) 174 The Indivior 2024 U.K.
Savings Related Share Option Plan (the Sharesave Plan ) 178 The Indivior U.S.
Employee Stock Purchase Plan (the ESPP ) 180 The Indivior Deferred Bonus Plan 2018 (the DBP ) 182 Indivior PLC Employee Benefit Trust 184 Indivior Inc.
Profit Sharing and 401(k) Plan (the 401(k) Plan ) 184 Indivior Inc.
Deferred Compensation Plan ( DCP ) 184 Deeds of Indemnity 185 Malus and Clawback 185 Indivior PLC Executive Compensation Clawback Policy 186 Executive Financial Recoupment Program 186 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters.
198 SIGNATURES 199 ii GLOSSARY Aelis means Aelis Farma, a French company from whom we obtained an exclusive option for AEF0117, a synthetic CB1 specific signaling inhibitor designed to treat cannabis-related disorders.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →